香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 除本公告另有界定者外，本公告所用詞彙與博泰車聯網科技（上海）股份有限公司（「本公司」） 日期為2025年9月22日的香港招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。 有意投資者於決定是否投資於發售股份前，務請細閱招股章程中有關下文所述全球發售的詳細 資料。任何有關發售股份的投資決定應僅依據招股章程所提供的資料作出。 本公告不得直接或間接於或向美國境內（包括其領土及屬地、美國任何州及哥倫比亞特區）發 佈、刊發、分發。本公告並不構成或組成於美國或任何其他司法管轄區購買或認購證券的任 何要約或招攬的一部分。本公告所述證券並無亦不會根據《1933年美國證券法》（經不時修訂） （「美國證券法」）或美國任何州或其他司法管轄區的證券法登記。除非進行獲豁免遵守美國證券 法的登記規定或 ...

香港联交所最新资料显示，9月22日，龙资源(01712)股东将股票存入万基证券，存仓市值2.27亿港元， 占比20%。 龙资源公告，配售事项的所有条件经已达成，并已于2025年9月22日完成交割。合共3161.93万股配售股 份已由配售代理按每股5.61港元的配售价成功配售予不少于六名承配人。3161.93万股配售股份占紧接完 成前的公司已发行股份总数20.0%，并占配发及发行所有配售股份后经扩大的公司已发行股份总数约 16.67%。概无承配人于完成后成为主要股东。 ...

Group 1 - The core point of the article is that Ying Sheng Science (00209) has completed a placement agreement, issuing a total of 30.95 million shares at a price of HKD 0.35 per share, which represents approximately 16.67% of the company's expanded issued share capital as of the announcement date [1][1][1] - On September 19, shareholders deposited shares into Imagi Brokerage Limited, with a market value of HKD 8.9759 million, accounting for 20% [1][1][1] - All conditions outlined in the placement agreement have been met, and the placement was completed according to the terms and conditions of the agreement [1][1][1]

配售股份的总面值将为30.95万港元。配售事项的所得款项总额将为1083.3万港元。经扣除所有相关开支 后，配售事项的所得款项净额估计约为1032万港元，其约50%拟用作偿还贷款，及约50%拟用作集团营 运资金及一般企业用途。 9月11日，瀛晟科学发布公告，于当日交易时段后，公司与配售代理订立配售协议，据此，配售代理同 意按悉数包销基准按每股配售股份0.350港元的价格为及代表公司向不少于六名承配人配售3095.15万股 新股份，占经配售事项扩大后公司已发行股份总数约16.67%。配售股份将根据一般授权配发及发行。 香港联交所最新资料显示，9月16日，瀛晟科学(00209)股东将股票由希望证券转入中国银行(香港)，转 仓市值372.61万港元，占比8.45%。 ...

公司已于2025年9月2日以每股H股29.28港元的配售价成功向不少于6名承配人(为独立专业或机构投资 者)配发及发行合共4002.56万股新H股，相当于经配售及已发行配售股份扩大后已发行H股数目的 9.02%。 9月2日，赣锋锂业发布公告，公司配售协议中载列的所有配售先决条件已获满足(包括获得上市批准)， 配售于2025年9月2日完成。 香港联交所最新资料显示，9月4日，赣锋锂业（002460）(01772)股东将股票由法国巴黎银行转入花旗 银行，转仓市值5.25亿港元，占比3.89%。 ...

Core Viewpoint - Shandong Gold announced a placement agreement to issue up to 136.5 million H-shares at a price of HKD 28.58 per share, aiming to raise approximately HKD 3.89242 billion for debt repayment [1] Group 1 - The placement is scheduled to be completed on September 2, 2025, before the trading session on the Hong Kong Stock Exchange [1] - The net proceeds from the placement are expected to be approximately HKD 3.89242 billion, assuming all shares are successfully placed [1] - The funds raised will primarily be used to repay the company's debts [1]

Group 1 - The company, Chudi Holdings, announced a plan to issue up to 200 million new shares at a price of HKD 0.063 per share, representing a discount of approximately 10% to the closing price on the announcement date [1] - This share placement will result in an increase of approximately 14.29% in the enlarged share capital of the company [1] - The estimated net proceeds from this placement are approximately HKD 12.1 million, which will be used for the company's general working capital [1]

Core Viewpoint - The company, Geely Pharmaceutical, announced a placement and subscription agreement to sell 52,400,000 shares at a price of HKD 16.45 per share, representing a discount of approximately 9.9% from the last closing price of HKD 18.26 on August 18, 2023 [1] Group 1 - The net proceeds from the subscription are expected to be approximately HKD 467.69 million after deducting commissions and estimated expenses [1] - Approximately 90% of the net proceeds is intended for the clinical trial development of subcutaneous and oral peptide candidates related to obesity [1] - About 10% of the net proceeds is suggested to be used for working capital and other general corporate purposes [1]

Core Viewpoint - The company, Qianxin Biotechnology-B (02509.HK), has announced a placement agreement to issue 5 million shares at a price of HKD 20.0 per share, which represents a discount of approximately 10.95% from the market price on August 15 [1][2] Group 1 - The placement shares represent approximately 2.25% of the total issued shares as of the announcement date and about 2.20% of the total issued shares after the placement [1] - The placement is being conducted by CICC as the placement agent, with the sole subscriber being TruMed Health Innovation Fund LP, a Cayman Islands registered exempt limited partnership focused on healthcare stocks [1] - The expected total proceeds from the placement are approximately HKD 100 million, with a net amount of about HKD 99 million after expenses [2] Group 2 - Approximately 60% of the net proceeds will be used to repay existing interest-bearing bank loans, which have increased due to additional borrowing for R&D expenses, thereby improving the company's financial position [2] - About 30% of the net proceeds will be allocated for the development of new product pipelines, including QX027N, QX031N, and QX035N [2] - The remaining 10% of the net proceeds will be used for working capital and other corporate purposes [2]

Core Viewpoint - Chuanghui Jewelry (08537) has successfully completed a placement of 60 million shares at a price of HKD 0.144 per share, raising approximately HKD 8.3 million for operational and general corporate purposes [1] Group 1 - The placement was completed on August 15, 2025, and involved at least six subscribers [1] - The net proceeds from the placement will be used for the group's operational funding and general corporate purposes, including employee costs, rent, procurement, and other administrative expenses [1] - The company anticipates utilizing the proceeds by the end of 2026 [1]